帕瑞瑞韦

帕瑞瑞韦（CAS 1216941-48-8）的公开数据库记录，列此仅供独立核对。

物理形态与操作说明

• At concentrations approximately 6 and 1.8 times the therapeutic concentrations of paritaprevir and ombitasvir, the combination did not prolong QTc to any clinically relevant extent.

这个物质在各数据库里的编号

数据库记载的用途

• When used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie, paritaprevir is
• Breast Feeding; Lactation; Milk, Human; Antiviral Agents; Protease Inhibitors
• Mechanisms of Action [MoA] - HCV NS3/4A Protease Inhibitors
• Established Pharmacologic Class [EPC] - Hepatitis C Virus NS3/4A Protease Inhibitor
• Mechanisms of Action [MoA] - Organic Anion Transporting Polypeptide 1B1 Inhibitors
• Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors

它在各数据库里的别名

Paritaprevir; 1216941-48-8; Veruprevir; ABT-450; Veruprevir anhydrous; ABT450; OU2YM37K86; ABT 450; DTXSID601027922; VIEKIRAX COMPONENT PARITAPREVIR; CHEBI:85188; empty; paritaprevirum; RefChem:170090; DTXCID501513483; 1221573-85-8

计算机算出的分子描述符

数据库摘要

Paritaprevir · CAS 1216941-48-8 · C40H43N7O7S. UNII OU2YM37K86.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。